(function(){var loadHandler=window['sl_{234E3818-5100-4EEE-8191-9D688D9A81FF}'];loadHandler&&loadHandler(20, '<div id="spr0_993b719"><div id="spr1_993b719" class="kern slide"><img id="img8_993b719" src="data/img0.png" width="720px" height="405px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_993b719" class="kern slide"><div id="svg0_993b719" style="left:-0.693px;top:-5.182px;"><svg width="31" height="415" viewBox="0 0 31 415"><path fill="#c00000" fill-opacity="0.8" d="M0,0 h30.345 v414.682 h-30.345 Z"/></svg></div><div id="spr3_993b719" style="left:29.652px;top:418.391px;"><div style="width:0px;"><span id="txt0_993b719" data-width="654.319336" style="left:7.2px;top:4.513px;">Red blood cell compatibility testing consists of typing for ABO and Rh(D) antigens,</span></div><div style="width:0px;"><span id="txt1_993b719" data-width="664.338867" style="left:7.2px;top:26.113px;">screening the plasma for non-ABO antibodies, and crossmatching prospective RBC</span></div><div style="width:0px;"><span id="txt2_993b719" data-width="631.371094" style="left:7.2px;top:47.713px;">units. Group O, A, and B persons have naturally occurring strong plasma anti-A</span></div><div style="width:0px;"><span id="txt3_993b719" data-width="652.350586" style="left:7.2px;top:69.313px;">and/or anti-B to the antigens they lack, and RBC units must be ABO compatible to</span></div><div style="width:0px;"><span id="txt4_993b719" data-width="648.307617" style="left:7.2px;top:90.913px;">avoid hemolytic transfusion reactions. D-negative persons can easily make anti-D</span></div><div style="width:0px;"><span id="txt5_993b719" data-width="663.363281" style="left:7.2px;top:112.513px;">when exposed to D-positive red blood cells and should normally receive D-negative</span></div><div style="width:0px;"><span id="txt6_993b719" data-width="659.302734" style="left:7.2px;top:134.113px;">red blood cells. This is especially important for girls and young women to avoid risk</span></div><div style="width:0px;"><span id="txt7_993b719" data-width="643.341797" style="left:7.2px;top:155.713px;">of hemolytic disease of the newborn in future D-positive fetuses. One to 2% of all</span></div><div style="width:0px;"><span id="txt8_993b719" data-width="604.335938" style="left:7.2px;top:177.313px;">patients, and 5 to 20% of multi-transfused patients have non-ABO hemolytic</span></div><div style="width:0px;"><span id="txt9_993b719" data-width="628.426758" style="left:7.2px;top:198.913px;">alloantibodies to Rh and other blood group antigens. These antibodies must be</span></div><div style="width:0px;"><span id="txt10_993b719" data-width="645.407227" style="left:7.2px;top:220.513px;">identified so that RBC units negative for the target antigens can be given to avoid</span></div><div style="width:0px;"><span id="txt11_993b719" data-width="607.306641" style="left:7.2px;top:242.113px;">hemolysis. After these “type and screen” tests, donor red blood cell units are</span></div><div style="width:0px;"><span id="txt12_993b719" data-width="614.285156" style="left:7.2px;top:263.713px;">crossmatched for the patient, either by computer confirmation or, if significant</span></div><div style="width:0px;"><span id="txt13_993b719" data-width="642.331055" style="left:7.2px;top:285.313px;">antibodies are present, by serological crossmatching of plasma versus donor red</span></div><div style="width:0px;"><span id="txt14_993b719" data-width="636.328125" style="left:7.2px;top:306.913px;">blood cells. Compatibility testing routinely takes 45 to 60 minutes or longer if red</span></div><div style="width:0px;"><span id="txt15_993b719" data-width="649.775391" style="left:7.2px;top:328.513px;">blood cells alloantibodies, warm (IgG), or cold (IgM) autoantibodies are present. If</span></div><div style="width:0px;"><span id="txt16_993b719" data-width="626.317383" style="left:7.2px;top:350.113px;">red blood cells must be given emergently before testing is completed, uncross-</span></div><div style="width:0px;"><span id="txt17_993b719" data-width="663.372070" style="left:7.2px;top:371.713px;">matched group O red blood cells are the best choice, after weighing the risk of non-</span></div><div style="width:0px;"><span id="txt18_993b719" data-width="614.364258" style="left:7.2px;top:393.313px;">ABO hemolytic red blood cell antibodies. In an emergency, as a guide to help</span></div><div style="width:0px;"><span id="txt19_993b719" data-width="564.257813" style="left:7.2px;top:414.913px;">remember that group O is a “universal donor,” think of the “O” in donor.</span></div></div><div id="spr4_993b719" style="left:29.652px;top:22.5px;"><div style="width:0px;"><span id="txt20_993b719" data-width="256.787109" style="left:217.049px;top:5.122px;">Blood Compatibility</span></div></div><div id="spr5_993b719" style="left:76px;top:117px;"><div style="width:0px;"><span id="txt21_993b719" data-width="91.037109" style="left:115.5px;top:12.586px;">Emergency</span></div></div><div id="spr6_993b719" style="left:76px;top:117px;"><img id="img0_993b719" src="data/img104.png" width="324" height="47" alt=""/></div><div id="spr7_993b719" style="left:76px;top:117px;"><div style="width:0px;"><span id="txt22_993b719" data-width="91.037109" style="left:115.5px;top:11.012px;">Emergency</span></div></div><div id="spr8_993b719" style="left:227px;top:161px;"><img id="img1_993b719" src="data/img105.png" width="22" height="20" alt=""/></div><div id="spr9_993b719" style="left:76px;top:178px;"><div style="width:0px;"><span id="txt23_993b719" data-width="263.091797" style="left:29.5px;top:12.819px;">Uncross-matched group O RBCs</span></div></div><div id="spr10_993b719" style="left:76px;top:178px;"><img id="img2_993b719" src="data/img106.png" width="324" height="48" alt=""/></div><div id="spr11_993b719" style="left:76px;top:178px;"><div style="width:0px;"><span id="txt24_993b719" data-width="263.091797" style="left:29.5px;top:11.244px;">Uncross-matched group O RBCs</span></div></div><div id="spr12_993b719" style="left:227px;top:222px;"><img id="img3_993b719" src="data/img107.png" width="22" height="20" alt=""/></div><div id="spr13_993b719" style="left:76px;top:239px;"><div style="width:0px;"><span id="txt25_993b719" data-width="302.141602" style="left:10px;top:13.051px;">Risk of non-ABO hemolytic antibodies</span></div></div><div id="spr14_993b719" style="left:76px;top:239px;"><img id="img4_993b719" src="data/img108.png" width="324" height="48" alt=""/></div><div id="spr15_993b719" style="left:76px;top:239px;"><div style="width:0px;"><span id="txt26_993b719" data-width="302.141602" style="left:10px;top:11.476px;">Risk of non-ABO hemolytic antibodies</span></div></div><div id="spr16_993b719" style="left:109px;top:310px;"><div style="width:0px;"><span id="txt27_993b719" data-width="69.029297" style="left:102.363px;top:10.02px;">Group O</span></div></div><div id="spr17_993b719" style="left:109px;top:310px;"><img id="img5_993b719" src="data/img109.png" width="275" height="42" alt=""/></div><div id="spr18_993b719" style="left:109px;top:310px;"><div style="width:0px;"><span id="txt28_993b719" data-width="69.029297" style="left:102.363px;top:8.445px;">Group O</span></div></div><div id="spr19_993b719" style="left:370px;top:310px;"><div style="width:0px;"><span id="txt29_993b719" data-width="126.061523" style="left:73.522px;top:10.02px;">Universal donor</span></div></div><div id="spr20_993b719" style="left:370px;top:310px;"><img id="img6_993b719" src="data/img110.png" width="274" height="42" alt=""/></div><div id="spr21_993b719" style="left:370px;top:310px;"><div style="width:0px;"><span id="txt30_993b719" data-width="126.061523" style="left:73.522px;top:8.445px;">Universal donor</span></div></div><div id="spr22_993b719" style="left:413px;top:105px;"><img id="img7_993b719" src="data/img111.png" width="276" height="193" alt=""/></div></div></div>');})();